[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-inflammation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-inflammation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,66,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100323577","early-phase-1-pet-imaging-ccr2-in-lung-inflammation-100323577",false,"NCT03492762","PET Imaging CCR2 in Lung Inflammation","Inclusion Criteria:\n\n* Men or women 21 years of age or older who have never smoked or current smokers who smoked at least 10 cigarettes per day (1\u002F2 pack) and have smoked at least 100 cigarettes (5 packs) over the past month.\n* Screening FEV1 and FVC \\> 80% of predicted\n* Capable of lying still and supine within the PET\u002FCT and PET\u002FMR scanner for \\~1 hour and follow instructions for breathing protocol during the CT portion\n* No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year\n* No known history of cardiac, pulmonary, hepatic or renal disease or diabetes\n* No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol specified imaging sessions\n* Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol\n* BMI ≤ 35\n\nExclusion Criteria:\n\n* Currently enrolled in another study using an investigational drug\n* Pregnancy (confirmed by urine pregnancy test)\n* Active symptoms or history of cardiac, pulmonary, hepatic or renal disease or diabetes\n* Currently taking any prescription medications\n* Presence of an implanted device that is incompatible with CT or MRI scanning\n* Creatinine \\> 1.30 mg\u002FdL, AST \\> 50 Units\u002FL, ALT \\> 55 Units\u002FL, or total bilirubin \\> 1.2 mg\u002FdL",true,"ALL","21 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The primary objective of this study is to assess the lung distribution of the Positron Emission Tomography (PET) imaging radiotracer Cu-DOTA-ECL1i, which binds to the specific population inflammatory cells, in patients with fibrotic lung diseases. This objective includes sub-studies to assess radiotracer distribution in the lung, the reproducibility of PET scans and the relationship of the scan to distribution of inflammatory cells in human lung tissue. The overall goal is to assess the potential of the radiotracer to track inflammatory cells in lung diseases.",[26],"Lung Inflammation","RECRUITING","2026-04-29",{"date":30,"type":31},"2026-05-01","ACTUAL",{"date":33,"type":31},"2018-02-27",{"date":35,"type":20},"2027-12-31",{"name":37,"class":38},"Washington University School of Medicine","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100504917","cough-capture-as-a-portal-into-the-lung-100504917","NCT05854563","Cough Capture as a Portal Into the Lung","Genetics of Lung Disease (Exhaled Breath DNA Methylation in Lung Carcinogenesis)","CC1","Inclusion Criteria:\n\n* Age: minimum age of 21 years\n* Gender: Male and Female adults\n* Ethnicity: All ethnic groups and races\n* Subjects undergoing bronchoscopy for diagnostic purposes or therapy\n* Subjects without a known diagnosis of lung cancer who are not scheduled for lung tissue collection procedures\n* Subjects with a known or suspected diagnosis of asthma or COPD and are scheduled for a visit at Montefiore Asthma or COPD Center and individual practices, and\u002For in-hospital with exacerbation\n\nExclusion Criteria:\n\n* Bleeding diathesis or known coagulopathy precluding clinically indicated biopsy (e.g., INR\\>1.3, PTTr\\>1.3), thrombocytopenia \\\u003C50,000, uremia with serum creatinine \\>3.0\n* Unstable angina\n* Recent myocardial infarction (within 3 months),\n* Uncontrolled congestive heart failure or severe pulmonary hypertension (mean PAP\\>75 mmHg)",{"count":49,"type":20},2000,"OBSERVATIONAL","The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection\u002Frisk assessment and diagnostic purposes. However, large macromolecules are not likely suspended nor readily detected in the breath. In particular, genomic DNA in the breath condensate (EBC) is very sparse, and where present, generally highly fragmented, not readily amenable to sequencing based assessments of DNA somatic mutation burden or distribution. Because gDNA (and protein) is challenging to obtain non-invasively from EBC, the study team considered alternative surrogate lower airway specimens. Cough capture is rarely done, and the investigator team is in the process of optimizing its collection. Importantly, the team will be evaluating how much of coughed material is from saliva contamination. Additionally, analyzing material that is target captured by capturing deep lung extracellular vesicles (EVs) using immobilized CCSP\u002FSFTPC antibodies targeting EVs from distal bronchiole Club and alveolar type 2 cells could circumvent the mouth contamination problem, leaving a non-invasive portal to the deep lung suitable for large molecules, and in turn suitable for myriad epidemiologic and clinical applications.\n\nThe investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL\u002Fbronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg\u002FMaslov labs. Finally, the investigator team will (Aim 3) test all airway specimens (cough, mouthwash and BAL) for lung surrogacy of cough, using proteins known to be specific for lung, as opposed to oral cavity\u002Fsaliva, in the Sidoli\u002Fproteomics core.\n\nThe investigator team envisions that the translational impact of non-invasively obtained DNA or protein markers could allow for more rapid acute clinical diagnoses, and facilitate precision prevention and\u002For early detection of many acute and chronic respiratory disorders, including lung cancer, asthma and COPD, acute and chronic infectious diseases, and indeed systemic disorders of inflammation and metabolism.",[53,54,55,56,26],"Lung Diseases","Lung Cancer","Lung Diseases, Obstructive","Lung Diseases, Interstitial","2026-01-12",{"date":59,"type":31},"2026-01-13",{"date":61,"type":31},"2023-03-28",{"date":63,"type":20},"2027-06",{"name":65,"class":38},"Albert Einstein College of Medicine",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":39},"100594950","clinical-application-study-of-petct-for-differential-diagnosis-of-non-small-cell-lung-cancer-100594950","NCT07026110","Clinical Application Study of PET\u002FCT for Differential Diagnosis of Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age 18-80 years;\n2. Imaging studies suspecting non-small cell lung cancer;\n3. Solid lung nodules (≥8 mm in diameter) diagnosed by chest ct, which are subject to 18F-FDG PET\u002FCT and surgical resection\u002Fbiopsy of lung nodules according to the NCCN guideline specifications for NSCLC in the 2024 edition;\n4. Patients or family members agreed to participate in this clinical study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Women during pregnancy and lactation;\n2. Persons with a history of surgery and trauma that significantly affects metabolic distribution and anatomical structure;\n3. Persons with severe other systemic diseases or known hypersensitivity to humanized monoclonal antibody products;\n4. Patient is unable to cooperate in completing the PET\u002FCT examination;\n5. Patient has participated in other clinical studies within the past year that have resulted in radiation exposures in excess of an effective dose of 50 mSv, in addition to the radiation exposures anticipated from participation in this clinical study;\n6. Patient should not participate in this clinical trial in the opinion of the investigator.","18 Years","80 Years",{"count":75,"type":20},100,[77],"NA","This study aims to explore the efficacy of Trop2, EpCAM-specific PET\u002FCT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel target-specific PET\u002FCT examinations and conventional 18F-FDG PET\u002FCT in the diagnosis and differential diagnosis of solid lung nodules.",[54,53,80,81,26],"Lung Neoplasms","Lung Cancer Metastatic",[83,84,85,86],"Trophoblast cell surface antigen 2 (Trop2)","Epithelial cell adhesion molecule(EpCAM)","ImmunoPET","Lung tumor","2025-06-10",{"date":89,"type":31},"2025-06-18",{"date":91,"type":31},"2024-12-23",{"date":93,"type":20},"2026-10-31",{"name":95,"class":38},"RenJi Hospital",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":39},"100555641","the-effects-of-different-ventilation-modes-on-patients-with-pulmonary-lobe-resection-100555641","NCT06514729","The Effects of Different Ventilation Modes on Patients With Pulmonary Lobe Resection","The Effects of Different Ventilation Modes on Patients With Plasma Inflammatory Factor and Respiratory Function in Patients With Pulmonary Lobe Resection","Inclusion Criteria:\n\nComprehensive examination and analysis of imaging, laboratory examination and other comprehensive examinations, the diagnosis is clear, which is in line with lobe resection surgical indications\n\nAge 18-75 years old, the gender is not limited;\n\nASA grading Ⅰ \\~ III level;\n\nIt is expected that the single lung ventilation time is ≥1 hours, and ≤3 hours\n\nExclusion Criteria:\n\nEmergency surgery;\n\nThere is a taboos on the existence of systemic anesthesia;\n\nThere is a history of acute chronic upper respiratory infections in the past January;\n\nPrevious bronchial asthma, chronic obstructive pulmonary disease, bronchial dilatation, phthisis ,aspergillosis , acute respiratory distress syndrome or history of respiratory failure;\n\nMerge the function of important organs such as heart, liver, and kidney;\n\nThere was a history of chest surgery and the history of trauma;\n\nPreoperative lung function test obvious abnormal abnormal abnormalities (1 second of exhalation (FEV1) \\\u003C60%);\n\nPatients refuse to participate in the clinical trial","75 Years",{"count":105,"type":20},102,[77],"The objective of this study was to discuss the effects of different ventilation modes on patients with plasma inflammatory factor and respiratory function in patients with pulmonary removal.",[109,26],"Lung Injury","2024-07-17",{"date":112,"type":31},"2024-07-23",{"date":114,"type":31},"2024-01-01",{"date":116,"type":20},"2025-05",{"name":118,"class":38},"Mao Enting"]